Humacyte’s (HUMA) “Buy” Rating Reaffirmed at BTIG Research

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating restated by equities research analysts at BTIG Research in a report issued on Monday,Benzinga reports. They currently have a $2.00 price objective on the stock. BTIG Research’s price objective points to a potential upside of 48.15% from the company’s previous close.

Other equities analysts also recently issued research reports about the company. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Humacyte in a research report on Tuesday, May 26th. Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a research report on Friday, April 10th. Benchmark raised their target price on Humacyte to $2.00 and gave the company a “speculative buy” rating in a research report on Monday, June 1st. D. Boral Capital restated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research report on Tuesday, April 28th. Finally, Wall Street Zen upgraded Humacyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Humacyte has a consensus rating of “Moderate Buy” and a consensus target price of $6.43.

Humacyte Price Performance

Shares of HUMA opened at $1.35 on Monday. Humacyte has a 52 week low of $0.55 and a 52 week high of $2.93. The company has a quick ratio of 3.32, a current ratio of 3.93 and a debt-to-equity ratio of 5.46. The company has a market capitalization of $299.73 million, a price-to-earnings ratio of -2.37 and a beta of 2.45. The stock’s 50-day moving average price is $0.89 and its 200-day moving average price is $1.03.

Humacyte (NASDAQ:HUMA) last announced its earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. The business had revenue of $0.50 million during the quarter, compared to the consensus estimate of $1.46 million. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%. On average, sell-side analysts predict that Humacyte will post -0.32 EPS for the current year.

Insiders Place Their Bets

In other news, insider Shamik J. Parikh sold 45,887 shares of Humacyte stock in a transaction on Monday, May 18th. The stock was sold at an average price of $0.90, for a total value of $41,298.30. Following the completion of the sale, the insider directly owned 272,713 shares of the company’s stock, valued at approximately $245,441.70. The trade was a 14.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Dale A. Sander sold 45,887 shares of Humacyte stock in a transaction on Monday, May 18th. The shares were sold at an average price of $0.90, for a total value of $41,298.30. Following the completion of the sale, the chief financial officer directly owned 267,213 shares of the company’s stock, valued at $240,491.70. The trade was a 14.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Prudential Financial Inc. acquired a new position in Humacyte during the 2nd quarter worth $28,000. Financial Advisors Network Inc. purchased a new stake in Humacyte during the 2nd quarter worth about $28,000. Truist Financial Corp purchased a new stake in Humacyte during the 3rd quarter worth about $28,000. Cerity Partners LLC purchased a new stake in Humacyte during the 2nd quarter worth about $35,000. Finally, Equitable Holdings Inc. purchased a new stake in Humacyte during the 3rd quarter worth about $29,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.